Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.52%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.54%AUDUSD-1.45%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.86%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.69%CHFJPY-0.68%CADJPY-0.67%NZDJPY-0.66%USDCHF+0.62%GBPUSD-0.62%USDCAD+0.59%EURUSD-0.58%NZDUSD-0.55%AUDSGD-0.51%USDZAR+0.44%AUDDKK-0.44%GBPTRY+0.41%NZDMXN+0.41%USDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%EURZAR+0.29%GBPMXN-0.28%GBPZAR+0.28%USDNOK+0.27%USDTRY+0.21%USDSEK+0.20%CHFNOK+0.20%USDPLN+0.20%EURCNH-0.18%NOKJPY-0.16%USDILS+0.16%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.13%EURNOK+0.13%USDCNH-0.12%USDJPY-0.11%GBPSGD-0.09%EURSGD-0.08%PLNJPY-0.08%GBPNZD-0.08%USDSGD+0.06%EURSEK+0.06%SGDJPY+0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%NZDCHF+0.04%USDCOP-0.04%EURCHF+0.04%EURCZK+0.04%EURNZD-0.03%CADCHF+0.03%USDHKD-0.02%CHFSGD-0.01%NZDCAD+0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.83%XPTUSD-0.74%W1-0.53%C1-0.41%XAUUSD-0.34%GAUUSD-0.34%GAGUSD-0.30%XAGUSD-0.30%HG1-0.25%UKOIL+0.21%S1-0.17%USOIL-0.08%BTCUSD-3.00%ETHUSD+57.77%USDTUSD0.00%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.20%XMRUSDT-1.74%DOGEUSD+55.95%LINKUSD-2.81%XLMUSD-3.27%BCHUSDT-3.12%LTCUSD+47.50%UNIUSD-2.50%SUIUSD-2.33%TONUSD+59.18%HBARUSDT-4.83%TAOUSDT-2.55%AAVEUSD-2.89%ONDOUSDT-4.61%ICPUSDT-1.52%DOTUSDT-3.36%WLDUSDT-3.20%ARBUSDT-5.21%ATOMUSDT-2.01%INJUSDT-6.85%STXUSDT-2.39%PYTHUSDT+0.21%TIAUSDT-2.54%FETUSDT-4.01%JUPUSDT+0.82%SEIUSDT-4.48%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-2.25%POLUSDT-1.58%WIFUSDT-2.25%AXSUSDT-2.47%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-6.30%GALAUSDT-1.65%DYDXUSDT-2.37%ORDIUSDT-2.00%NOTUSDT-0.74%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.52%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.54%AUDUSD-1.45%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.86%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.69%CHFJPY-0.68%CADJPY-0.67%NZDJPY-0.66%USDCHF+0.62%GBPUSD-0.62%USDCAD+0.59%EURUSD-0.58%NZDUSD-0.55%AUDSGD-0.51%USDZAR+0.44%AUDDKK-0.44%GBPTRY+0.41%NZDMXN+0.41%USDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%EURZAR+0.29%GBPMXN-0.28%GBPZAR+0.28%USDNOK+0.27%USDTRY+0.21%USDSEK+0.20%CHFNOK+0.20%USDPLN+0.20%EURCNH-0.18%NOKJPY-0.16%USDILS+0.16%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.13%EURNOK+0.13%USDCNH-0.12%USDJPY-0.11%GBPSGD-0.09%EURSGD-0.08%PLNJPY-0.08%GBPNZD-0.08%USDSGD+0.06%EURSEK+0.06%SGDJPY+0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%NZDCHF+0.04%USDCOP-0.04%EURCHF+0.04%EURCZK+0.04%EURNZD-0.03%CADCHF+0.03%USDHKD-0.02%CHFSGD-0.01%NZDCAD+0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.83%XPTUSD-0.74%W1-0.53%C1-0.41%XAUUSD-0.34%GAUUSD-0.34%GAGUSD-0.30%XAGUSD-0.30%HG1-0.25%UKOIL+0.21%S1-0.17%USOIL-0.08%BTCUSD-3.00%ETHUSD+57.77%USDTUSD0.00%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.20%XMRUSDT-1.74%DOGEUSD+55.95%LINKUSD-2.81%XLMUSD-3.27%BCHUSDT-3.12%LTCUSD+47.50%UNIUSD-2.50%SUIUSD-2.33%TONUSD+59.18%HBARUSDT-4.83%TAOUSDT-2.55%AAVEUSD-2.89%ONDOUSDT-4.61%ICPUSDT-1.52%DOTUSDT-3.36%WLDUSDT-3.20%ARBUSDT-5.21%ATOMUSDT-2.01%INJUSDT-6.85%STXUSDT-2.39%PYTHUSDT+0.21%TIAUSDT-2.54%FETUSDT-4.01%JUPUSDT+0.82%SEIUSDT-4.48%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-2.25%POLUSDT-1.58%WIFUSDT-2.25%AXSUSDT-2.47%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-6.30%GALAUSDT-1.65%DYDXUSDT-2.37%ORDIUSDT-2.00%NOTUSDT-0.74%RONINUSDT-2.92%
IB

IDEAYA Biosciences, Inc. (IDYA)

NASDAQ • Healthcare

$26.49
-$0.91 (-3.3%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$27.04
Day Range$26.02 - $27.53
Avg. Volume (3M)1.1M
Market Cap$2.5B
52 Week Range
$26.02$42.68
Next EarningsIn 89 daysFeb 16, 2027

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$10.2M100%
Gross Profitminus cost of goods$10.2M100%

Fundamentals & Financials

Revenue (TTM)
$36.5M
Net Income (TTM)
-$420M
EPS (TTM)
-$4.49
ROA (TTM)
-34.54%
Current Ratio
9.04

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-3.7%Q2 2026-$1.11
-15.1%Q3 2026-$1.22
-3.4%Q4 2026-$1.22
Next

Feb 16

in 89 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -3.4%

IDEAYA Biosciences’ EPS trailed consensus in the third fiscal quarter of 2026, with EPS of -$1.22 coming in below the -$1.18 estimate by -$0.04, as the company posted sharply lower revenue; the results were reported on November 3, 2026. Revenue fell 95% to about $10.2 million, down from roughly $207.8 million a year ago, as the quarter reflected a much smaller top line versus the prior-year period. Profitability remained negative, with operating income of about -$137.6 million alongside a net loss of roughly -$125.7 million, compared with net income of about $119.2 million a year ago, and the reported EPS compared with $1.33 in the year-ago quarter. For the next period, consensus calls for EPS of -$1.13 on revenue of $18.6 million.

View full earnings history

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a biotechnology company focused on precision oncology, developing targeted cancer medicines for molecularly defined patient groups. In FY2025, it generated $218.7 million in revenue. The company centers its approach on synthetic lethality, using genetic and molecular diagnostic selection to match therapies to specific tumor vulnerabilities.

Name
IDEAYA Biosciences, Inc.
CEO
Yujiro S. Hata
Industry
Healthcare
Year Founded
2015
Employees
145

Today's Snapshot

AI-generated

IDYA closed 3.3% lower on heavier trading than usual. IDEAYA Biosciences outlined an FDA-backed late-stage trial plan for IDE849, an experimental cancer drug.

Trading Volume

Above 10d avg 1.1M

1.4M

vs S&P 500 Today

Strong Underperformance

-3.06%

Updated: November 18, 2026 at 21:11 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
IDYA exhibits broad selling pressure across moving averages and momentum, trading around $26.49 well below most short- and long-term averages and with the classic pivot near $28.64 acting as resistance. MACD and CCI are strongly negative and ADX indicates a pronounced downward trend, while RSI and stochastic readings are deeply oversold, reflecting exhausted oscillators rather than strength. ATR shows moderate volatility and OBV is negative, pointing to volume-confirmed distribution. Technical takeaway: pervasive weakness across trend, momentum and volume metrics supports a strong sell bias despite oversold oscillators.
All signals
  • EMA (5 indicators)$30.14 - $34.61
    Sell
  • RSI (14)27.09
    Buy
  • Stochastic %K (14, 3, 3)6.40
    Buy
  • MACD Level (12, 26)-1.71
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.